‘Hope on the horizon' as drugs assessed for Alzheimer's prevention
Some 138 treatments are being assessed in clinical trials.
A third of drugs currently being trialled are 'repurposed' medications that are already being used to tackle other diseases, including diabetes, multiple sclerosis and cholesterol, according to the new review.
One such trial is assessing whether semaglutide, the main ingredient for the weight loss and diabetes drug Ozempic and weight loss drug Wegovy, can slow the progression of dementia.
And four late-stage trials are looking at preventing disease.
Experts said that drugs targeting amyloid protein build up in the brain, such as lecanemab and donanemab, are 'only one part of the overall strategy' as they expressed excitement over the variety of new drugs, which are being tested among patients.
The new review of Alzheimer's disease in clinical trials in 2025 found 182 clinical trials assessing the impact of 138 drugs.
The number of trials represents an 11% increase on the previous year, according to the review, which was led by an expert from the University of Nevada in the US and has been published in the journal Alzheimer's and Dementia: Translational Research and Clinical Interventions.
Commenting on the paper, Dr Sheona Scales, director of research at Alzheimer's Research UK, said: 'This year has really given us real cause for optimism.'
She said that as well as more drugs coming through the pipeline, the treatment targets are 'more diverse' and 'looking at all stages of the disease'.
She added: 'What this paper is showing us is that the pipeline of drug development is growing, it's diversifying and accelerating.'
'This latest report shows us that there is hope on the horizon for people with Alzheimer's, building on lecanemab and donanemab.'
Dr Emma Mead, chief scientific officer of the Oxford Drug Discovery Institute, added: 'Today we are at a tipping point in dementia research as we understand more and more about the diseases that drive dementia.
'This gives us opportunities to slow and ultimately stop this devastating condition and today's announcement demonstrates that researchers are able to translate these understandings towards potential new treatments.'
James Rowe, professor of cognitive neurology at the University of Cambridge and consultant neurologist, said: 'What strikes me is not just the number of new drugs, which is increasing year on year, but their range of targets (and) the range in which they work, giving us multiple shots on goal.'
On the drugs which are being investigated for the prevention of disease, Prof Rowe said: 'One of the most exciting things of this report is the number of large-scale late-stage trials on prevention.
'And the aspiration to prevent, not just treat, is starting to be seen in the figures we see in these charts today.'
He added: 'One way this can work is you take a treatment that you show to be working in people with symptoms with the illness, and then you simply bring it forward by some years.
'The ones that are in trial at the moment are really… bringing forward an effective treatment to earlier stage.'
For instance, people with a genetic risk of Alzheimer's could receive some drugs earlier to see if they protect against the disease.
On the repurposing of current drugs, Dr Mead said that it can usually take 10 to 15 years for new drugs to be tested and approved for use.
'Being able to repurpose drugs licensed for other health conditions could help to accelerate progress and help to open up other avenues to prevent or treat dementia causing diseases,' she said.
'A really promising example of this is the drug semaglutide, which is currently being trialled in people with mild cognitive impairment.'
Meanwhile, academics said lecanemab and donanemab, which can be used for treating mild cognitive impairment in Alzheimer's patients, are an 'important first step' in the battle against the disease.
The treatments were initially approved for UK use by regulators but then deemed not cost-effective for NHS use.
The National Institute for Health and Care Excellence (Nice) is taking more evidence on donanemab and lecanemab and is expected to announce its decision in the summer.
Dr Scales added: 'Lecanemab and donanemab have represented a huge leap forward in our understanding and ability to be able to treat Alzheimer's disease.
'What they've done is they've proved that we're able to modify the course of Alzheimer's disease, and what that has done is opened up the door to future treatments that we hope are more effective, easier to deliver and and able to deliver for our patients.'
She said studies are showing 'even more complexities' around Alzheimer's and that in the future, people may be treated with a combination of drugs, depending on when they are diagnosed and the type of dementia they have.
Dr Richard Oakley, associate director of research at Alzheimer's Society, said: 'This paper shows that 2025 is shaping up to be a landmark year for Alzheimer's disease drug development.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medical News Today
3 hours ago
- Medical News Today
Muscle loss from GLP-1 drugs like Ozempic may not be as high as thought
While past studies show that adults taking a GLP-1 medication can lose between 5-15% of their starting body weight, other research reports that a good portion of that weight loss comes from muscle loss. A new study says, via a mouse model, that muscle loss from GLP-1 medications like Ozempic may not be as high as recently thought. Researchers also found that the decrease in lean muscle mass was not all from skeletal muscles, but from other body tissues, including the polls estimate that one in every eight adults in the U.S. have taken a glucagon-like peptide-1 receptor agonist (GLP-1) — a class of prescription drugs originally used to treat type 2 diabetes that has gained popularity as a method of weight of GLP-1 medications include semaglutide, sold under the brand names Ozempic and Wegovy, and tirzepatide, sold under the brand names Zepbound and Mounjaro. Past studies show that adults taking a GLP-1 medication can lose between 5-15% of their starting body weight within one year. However, other research reports that about 25-39% of that weight loss is from muscle loss. Now, a new study recently published in the journal Cell Metabolism says, via a mouse model, that muscle loss from GLP-1 medications like Ozempic may not be as high as recently thought. Researchers also found that the decrease in lean muscle mass was not all from skeletal muscles, but from other body tissues, including the liver. Lean muscle mass loss not just from skeletal musclesFor this study, researchers used a mouse model to determine how GLP-1 medications like Ozempic affected lean muscle mass. Upon analysis, researchers found that Ozempic-related weight loss in mice resulted in a lean muscle mass decrease of about 10%, which is less than some previous studies report that as the mice lost weight, some skeletal muscles did decrease, while other muscles stayed the same. Researchers state that the muscle mass decrease is a return to baseline, as gaining fat is usually accompanied by a gain in skeletal muscle. Researchers found some mice experienced a decrease in strength in skeletal muscles that stayed almost the same researchers found that a good portion of the decrease in lean muscle mass did not come from skeletal muscles, but rather other tissues in the body, such as the liver, which they report reduced in size by almost half. It is not uncommon for the liver to decrease in size during weight loss, which can help reduce a person's risk for fatty liver disease.'If we want to really help the individuals who may be losing muscle mass, then we need to know that they're actually losing muscle mass,' Katsu Funai, PhD, associate professor of nutrition and integrative physiology in the University of Utah College of Health and the senior author on the study says in a press release. 'We have data in mice that suggest that things are not as straightforward as they might seem.'Working with a dietitian while taking GLP-1sMedical News Today spoke with Seth Kipnis, MD, FACS, FASMBS, director of bariatric and robotic surgery at Hackensack Meridian Jersey Shore University Medical Center in New Jersey, about this study, who commented that a drop in lean muscle mass is expected. Some muscle loss is inevitable'Any patient with a restricted diet and poor nutrition/protein will have a drop in muscle mass. The key of any weight loss program, surgical, medical or GLP-1 is adequate nutrition. Working with a registered dietitian is key to long-term success and avoiding complications of malnutrition.' — Seth Kipnis, MD, FACS, FASMBS'More and more people are taking these medications on a regular basis,' he continued. 'They are working well to control weight. We should know the side effects that can be caused in the long term so that patients can be counseled on how to avoid long-term issues.' Kipnis said he would like to see better long-term data as the next steps in this research. 'And are different outcomes found depending on the prescriber and the type of follow-up,' he added. 'It is our assumption that specialists in weight management and nutrition will have better outcomes than a primary care doctor that treats every disease. Obesity is a unique disease that requires specialists to manage.'Human trials needed to further analyze GLP-1s and muscle lossMNT also talked to Kais Rona, MD, a bariatric surgeon of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA.'As a physician who has treated and continues to treat many patients with GLP-1 medications such as Ozempic, I found this study quite interesting,' Rona said. 'Although the data in this study cannot be extrapolated directly to humans, it does shed some light on potentially important physiologic effects of the medication.' 'The decrease in lean mass with GLP-1 use was associated with a lesser decrease in skeletal muscle mass and a greater decrease in the size of metabolically active organs such as the liver. This can have important physiologic effects on metabolism and overall health. We also see a decrease in liver mass in patients undergoing weight loss surgery, which often leads to beneficial health effects. Importantly, this study also highlights the importance of determining the functional impact of muscle loss and whether that is reflected in a loss of strength as well.'— Kais Rona, MD'It's extremely important to continue to study the potential side effects, including the loss of lean muscle mass, associated with GLP-1 medications as it can have major effects on our healthcare system as a whole,' Rona added. 'Furthermore, we need to continue to broaden our understanding of the physiologic effects of these medications to optimize patient safety and overall outcomes.' Rona said the next best research step would be to perform randomized-controlled trials in humans to further analyze the effects of GLP-1 medications on lean mass as well as skeletal muscle mass. 'It would be important to evaluate its effects on muscle strength as well as function,' he added. 'Also to determine whether certain areas of the body are more susceptible to muscle loss as well as identifying preventive strategies to combat muscle loss.'
BBC News
3 hours ago
- BBC News
Redcar Council parking patrol CCTV cars to get £100k upgrade
A council has approved funding of £100,000 to upgrade CCTV car which captures footage of motorists flouting parking and traffic restrictions and introduce a second and Cleveland Council sanctioned spending on for new front and rear stingray cameras on its existing car which mainly patrols near in bus stops was another area set to be subject to increased monitoring, which in some instances blocked passengers from being picked up and dropped 2018 the enforcement vehicle had provided evidence leading to 2,450 penalty charge notices, the council said. A spending decision document said the greatest challenge for officers was the size of the borough and the number of schools with "significant challenges for repeated and equitable enforcement of restrictions".It said ensuring road safety around primary schools in particular on mornings and at home times was "imperative".A council spokesman said: "The authority is now looking to deploy a second enforcement vehicle which may be used in areas where crime and anti-social behaviour are identified as ongoing problems, as well as supporting public safety at events." The Labour-led authority signed off on £99,443 of funding, the Local Democracy Reporting Service sum included the cost of a five-year support and maintenance contract. Follow BBC Tees on X, Facebook, Nextdoor and Instagram.
Daily Mail
7 hours ago
- Daily Mail
Newborn left brain damaged 'by virus' after walk near $1m Martha's Vineyard home...now locals fear it's spreading
A newborn baby has been left with brain damage after being infected with a rare virus while on a family walk in Martha's Vineyard. The one-month-old baby, Lily Belle Sisco, was flown to Massachusetts General Hospital on July 24 with a persistent 102-degree fever. Lily later started having seizures and was determined to have viral encephalitis. The baby's family learned over the weekend that the cause of the newborn's illness was a tick bite and that the little girl had Powassan - a rare but very serious disease. The family of the infant said she has suffered brain damage from the infection, but is currently listed as stable and is receiving treatment at Massachusetts General Hospital in Boston. Tiffany and Marcus were shocked that a short walk in their Martha's Vineyard neighborhood caused their newborn to contract the severe illness. 'We certainly had no idea a 20-minute walk on the West Tisbury bike path beside our home, a walk we do most every day, could potentially cause my child her life,' parents Tiffany Sisco and Marcus Sisco wrote in a Facebook post on Saturday. The family live in a $1.3 million home in the West Tisbury town of Martha's Vineyard, according to public records. 'Please, please, please check yourselves, your children and your pets. It was the tiniest nymph tick the size of a needle tip,' the parents added. According to a Facebook page for the family business - Sisco Family Services, their company offers fence and gate contracting in the West Tisbury area. Lily's Aunt Ashlee Moreis created a GoFundMe to raise money for the family. 'While she has the best medical team in Boston her parents haven't left her side,' she wrote. She added that Rose, Lily's big sister, is being cared for on Martha's Vineyard by family while her parents are with their newborn. 'Marcus is the sole provider for their family,' the GoFundMe says. 'He has been by Lily's side every moment in this journey.' So far the fundraising page has raised over $27,000. The Sisco family said Lily is youngest person to contract Powassan in the world. They are hoping to get their story out so a case like their daughter's is never repeated. Powassan virus is a rare but serious virus spread through the bite of infected ticks that has become more common in recent years. Now, amidst one of the worst tick seasons in New England in a long time, cases are on the rise - and the disease is unpreventable and untreatable. The virus can be spread within just 15 minutes of the tick's bite, and early symptoms can include fever, headache and vomiting. More serious cases involve brain swelling, seizures and long-term neurological complications. Only one case of the Powassan virus had been recorded in Martha's Vineyard over the past 20 years, until now. This year alone Massachusetts has seen three confirmed cases. Most cases of the virus arise in the Northeast and Great Lakes region of Massachusetts from late spring through mid-fall, according to the Centers for Disease Control and Prevention. The disease is carried by nymph and adult deer ticks. 'The virus is present every year in a small percentage of deer ticks; fortunately, severe disease remains very rare,' Dr. Sam Telford, a Tufts University professor who has conducted research on Martha's Vineyard, said in a statement. His lab tested more than 3,500 nymph deer ticks between 2021 and 2024 and found that between one and two percent of deer ticks were infected.
